134 related articles for article (PubMed ID: 12586589)
1. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study.
Keldsen N; Havsteen H; Vergote I; Bertelsen K; Jakobsen A
Gynecol Oncol; 2003 Feb; 88(2):118-22. PubMed ID: 12586589
[TBL] [Abstract][Full Text] [Related]
2. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
Markman M; Blessing JA; Moore D; Ball H; Lentz SS
Gynecol Oncol; 1998 Jun; 69(3):226-9. PubMed ID: 9648592
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).
Rothenberg ML; Liu PY; Wilczynski S; Hannigan EV; Weiner SA; Weiss GR; Hunter VJ; Chapman JA; Tiersten A; Kohler PC; Alberts DS
Gynecol Oncol; 2001 Aug; 82(2):317-22. PubMed ID: 11531286
[TBL] [Abstract][Full Text] [Related]
4. [Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma].
Gershanovich ML; Livshits ME; Antipenkova VI
Vopr Onkol; 2000; 46(5):604-7. PubMed ID: 11202196
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.
Rustin GJ; Nelstrop AE; Crawford M; Ledermann J; Lambert HE; Coleman R; Johnson J; Evans H; Brown S; Oster W
J Clin Oncol; 1997 Jan; 15(1):172-6. PubMed ID: 8996139
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.
Sørensen P; Høyer M; Jakobsen A; Malmström H; Havsteen H; Bertelsen K
Gynecol Oncol; 2001 Apr; 81(1):58-62. PubMed ID: 11277650
[TBL] [Abstract][Full Text] [Related]
7. Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.
Moore DH; Valea F; Crumpler LS; Fowler WC
Gynecol Oncol; 1993 Oct; 51(1):109-12. PubMed ID: 8244164
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer.
Hauge MD; Long HJ; Hartmann LC; Edmonson JH; Webb MJ; Su J
Invest New Drugs; 1992 Nov; 10(4):299-301. PubMed ID: 1487403
[TBL] [Abstract][Full Text] [Related]
9. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer.
Vergote I; Himmelmann A; Frankendal B; Scheistrøen M; Vlachos K; Tropé C
Gynecol Oncol; 1992 Dec; 47(3):282-6. PubMed ID: 1473738
[TBL] [Abstract][Full Text] [Related]
10. Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer.
Moore DH; Fowler WC; Jones CP; Crumpler LS
Am J Obstet Gynecol; 1991 Sep; 165(3):573-6. PubMed ID: 1909840
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group.
Alberts DS; Jiang C; Liu PY; Wilczynski S; Markman M; Rothenberg ML
Int J Gynecol Cancer; 2004; 14(2):224-8. PubMed ID: 15086720
[TBL] [Abstract][Full Text] [Related]
12. Oral altretamine used as salvage therapy in recurrent ovarian cancer.
Chan JK; Loizzi V; Manetta A; Berman ML
Gynecol Oncol; 2004 Jan; 92(1):368-71. PubMed ID: 14751188
[TBL] [Abstract][Full Text] [Related]
13. Altretamine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group trial.
Zon RT; McClean J; Helman D; Ansari R; Picus J; Sandler A; Williams SD; Loehrer PJ
Invest New Drugs; 2001; 19(3):229-31. PubMed ID: 11561679
[TBL] [Abstract][Full Text] [Related]
14. Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine).
Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
Cancer Treat Rev; 1991 Mar; 18 Suppl A():23-9. PubMed ID: 1904305
[TBL] [Abstract][Full Text] [Related]
15. Phase II evaluation of altretamine for advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Rose PG; Blessing JA; Arseneau J
Gynecol Oncol; 1996 Jul; 62(1):100-2. PubMed ID: 8690279
[TBL] [Abstract][Full Text] [Related]
16. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma.
Johnson BL; Fisher RI; Bender RA; DeVita VT; Chabner BA; Young RC
Cancer; 1978 Nov; 42(5):2157-61. PubMed ID: 102417
[TBL] [Abstract][Full Text] [Related]
17. Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy.
Kwon YS; Nam JH; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT
J Korean Med Sci; 2009 Aug; 24(4):679-83. PubMed ID: 19654952
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
[No Abstract] [Full Text] [Related]
19. Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.
Lee CR; Faulds D
Drugs; 1995 Jun; 49(6):932-53. PubMed ID: 7641606
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study.
Frasci G; Comella G; Comella P; Conforti S; Mastrantonio P; Zullo F; Persico G
Gynecol Oncol; 1995 Jul; 58(1):68-73. PubMed ID: 7789893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
